Literature DB >> 16901594

The use of Markov chain Monte Carlo uncertainty analysis to support a Public Health Goal for perchloroethylene.

Tammie R Covington1, P Robinan Gentry, Cynthia B Van Landingham, Melvin E Andersen, Janet E Kester, Harvey J Clewell.   

Abstract

The current Public Health Goal (PHG) for perchloroethylene (PCE) was derived using upper-bound estimates of fractional PCE metabolism in humans. These estimates were in part obtained from a published evaluation of the uncertainty and variability in human PCE metabolism conducted using a physiologically-based pharmacokinetic (PBPK) model in a Markov chain Monte Carlo (MCMC) analysis; however, the data used in that analysis were limited to post-exposure PCE blood and exhaled air concentrations from a single study. A more recent study [Volkel, W., Friedewald, M., Lederer, E., Pahler, A., Parker, J., Dekant, W., 1998. Biotransformation of perchloroethene: dose-dependent excretion of trichloroacetic acid, dichloroacetic acid, and N-acetyl-S-(trichlorovinyl)-l-cysteine in rats and humans after inhalation. Toxicol. Appl. Pharmacol. 153(1), 20-27.] provides data on blood concentrations of PCE and its major metabolite, trichloroacetic acid (TCA), and urinary excretion of TCA following exposure of human subjects to lower concentrations of PCE (10-40ppm) than in previous studies. In the present effort, a new MCMC analysis was performed that focused on data from this study along with two others [Fernandez, J., Guberan, E., Caperos, J., 1976. Experimental human exposures to tetrachloroethylene vapor and elimination in breath after inhalation. Am. Ind. Hyg. Assoc. J. 37, 143-150; Monster, A., Boersma, G., Steenweg, H., 1979. Kinetics of tetrachloroethylene in volunteers; influence of exposure concentration and work load. Int. Arch. Occup. Environ. Health 42, 303-309.] providing data on PCE blood concentrations and urinary excretion of TCA. To provide an accurate prediction of TCA kinetics, the PBPK model used here includes a description of the metabolism of PCE to TCA in both the liver and kidney. The resulting upper 95th percentile estimates of fraction of PCE metabolized by inhalation and oral routes were 2.1 and 5.2%, respectively, compared to 58 and 79% used in the derivation of the PHG.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16901594     DOI: 10.1016/j.yrtph.2006.06.008

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  19 in total

1.  Incorporation of the glutathione conjugation pathway in an updated physiologically-based pharmacokinetic model for perchloroethylene in mice.

Authors:  Chimeddulam Dalaijamts; Joseph A Cichocki; Yu-Syuan Luo; Ivan Rusyn; Weihsueh A Chiu
Journal:  Toxicol Appl Pharmacol       Date:  2018-05-29       Impact factor: 4.219

2.  Reconstructing population exposures to environmental chemicals from biomarkers: challenges and opportunities.

Authors:  Panos G Georgopoulos; Alan F Sasso; Sastry S Isukapalli; Paul J Lioy; Daniel A Vallero; Miles Okino; Larry Reiter
Journal:  J Expo Sci Environ Epidemiol       Date:  2008-03-26       Impact factor: 5.563

3.  In vitro-in silico-based analysis of the dose-dependent in vivo oestrogenicity of the soy phytoestrogen genistein in humans.

Authors:  Rungnapa Boonpawa; Albertus Spenkelink; Ans Punt; Ivonne M C M Rietjens
Journal:  Br J Pharmacol       Date:  2017-07-11       Impact factor: 8.739

4.  Assessing drug distribution in tissues expressing P-glycoprotein using physiologically based pharmacokinetic modeling: identification of important model parameters through global sensitivity analysis.

Authors:  Frederique Fenneteau; Jun Li; Fahima Nekka
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-10-22       Impact factor: 2.745

5.  Quantitative Characterization of Population-Wide Tissue- and Metabolite-Specific Variability in Perchloroethylene Toxicokinetics in Male Mice.

Authors:  Chimeddulam Dalaijamts; Joseph A Cichocki; Yu-Syuan Luo; Ivan Rusyn; Weihsueh A Chiu
Journal:  Toxicol Sci       Date:  2021-08-03       Impact factor: 4.849

6.  Translational research to develop a human PBPK models tool kit-volatile organic compounds (VOCs).

Authors:  M Moiz Mumtaz; Meredith Ray; Susan R Crowell; Deborah Keys; Jeffrey Fisher; Patricia Ruiz
Journal:  J Toxicol Environ Health A       Date:  2012

Review 7.  Development of a human Physiologically Based Pharmacokinetic (PBPK) Toolkit for environmental pollutants.

Authors:  Patricia Ruiz; Meredith Ray; Jeffrey Fisher; Moiz Mumtaz
Journal:  Int J Mol Sci       Date:  2011-10-31       Impact factor: 5.923

8.  Application of physiologically based pharmacokinetic models in chemical risk assessment.

Authors:  Moiz Mumtaz; Jeffrey Fisher; Benjamin Blount; Patricia Ruiz
Journal:  J Toxicol       Date:  2012-03-19

9.  Reconstruction of Exposure to m-Xylene from Human Biomonitoring Data Using PBPK Modelling, Bayesian Inference, and Markov Chain Monte Carlo Simulation.

Authors:  Kevin McNally; Richard Cotton; John Cocker; Kate Jones; Mike Bartels; David Rick; Paul Price; George Loizou
Journal:  J Toxicol       Date:  2012-04-08

10.  Weighted Markov chains for forecasting and analysis in Incidence of infectious diseases in jiangsu Province, China.

Authors:  Zhihang Peng; Changjun Bao; Yang Zhao; Honggang Yi; Letian Xia; Hao Yu; Hongbing Shen; Feng Chen
Journal:  J Biomed Res       Date:  2010-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.